trending Market Intelligence /marketintelligence/en/news-insights/trending/_ZDP7N0oiytkQLataxPlHg2 content esgSubNav
In This List

Lupin, Cadila initiate voluntary recall of drugs in US

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Lupin, Cadila initiate voluntary recall of drugs in US

Lupin Ltd. and Cadila Healthcare Ltd.'s units initiated a voluntary recall of 111,648 units of duloxetine 30 mg delayed-release capsules and 19,812 bottles of paroxetine 30mg tablets from the U.S. market, respectively.

According to an enforcement report by the U.S. Food and Drug Administration, Lupin Pharmaceuticals Inc.'s class III recall for duloxetine was due to "failed dissolution specification" and Zydus Pharmaceuticals (USA) Inc.'s class II recall of paroxetine was due to the presence of foreign tablets/capsules as risperidone tablets were found in a bottle of paroxetine tablets.